Arch Therapeutics (OTCMKTS: ARTH) and Mazor Robotics (NASDAQ: MZOR) are both small medical companies, but which is top class stock? We will compare two companies based on the power of their dividends, valuations, analytical recommendations, risks, institutional ownership, earnings and profitability.
Earnings and Valuation
This table compares Arch Therapeutics and Mazor Robotics for top-line revenue, earnings per share, and valuation.
|Gross income||Price / Sales ratio||Net income||Earnings per share||Price / earnings ratio|
|Arch Therapeutics||ON||ON||– $ 7.78 million||($ 0.05)||-7.80|
|Mazor Robotics||$ 64.95 million||23.64||– $ 12.41 million||($ 0.50)||-116.64|
Arch Therapeutics has higher earnings, but lower revenue from Mazor Robotics. Mazor Robotics trading at a lower price than the profits of Arch Therapeutics, pointing out that it is currently more accessible than two shares.
Volatility and risk
Arch Therapeutics has a beta of 0.83, indicating that the price of the stock is 17% less volatile than the S & P 500. At the same time, Mazor Robotics has a beta of 1.32, indicating that stock price is 32% more unstable than S & P 500th
This is a breakdown of current ratings and recommendations for Arch Therapeutics and Mazor Robotics, as reported by MarketBeat.com.
|Sell a rating||Keep ratings||Buy a rating||Powerful purchase rating||Rating Rating|
Arch Therapeutics currently has a target price of $ 3.00, indicating a potential increase of 669.23%. Mazor Robotics has a target price of $ 51.67, suggesting a potential drop of 11.41%. Given the more consensual rating of Arch Therapeutics and the more likely success, stock analysts clearly demonstrate that Arch Therapeutics is more favorable than Mazor Robotics.
This table compares the net margin of Arch Therapeutics and Mazor Robotics, return on equity and return on assets.
|Net margin||Return on capital||Back to property|
Insider and Institutional Property
0.0% of Arch Therapeutics shares are owned by institutional investors. In parallel, 21.7% of Mazor Robotics shares are owned by institutional investors. Strong institutional ownership is an indicator that funds, large cash managers and hedge funds believe the stock is ready for long-term growth.
Arch Therapeutics wins Mazor Robotics on 7 of the 12 factors that are compared between the two stocks.
About Arch Therapeutics
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and leak control, as well as other benefits during surgery, trauma and emergency care. Its primary candidate for the product is AC5 Devices, synthetic biocompatible peptides that contain naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is headquartered in Framingham, Massachusetts.
About Mazoru Robotics
Mazor Robotics Ltd, together with its subsidiaries, is engaged in the development, production and marketing of medical devices for the support of surgical interventions in the field of orthopedics and neurosurgery in the United States and internationally. It works in the area of a surgical procedure with a computer, which allows the use of surgical instruments with high precision and minimal invasiveness and simplifies complex surgical procedures. Systems of surgical robot guides and complementary products of the company are used to carry out spinal and brain procedures in the correct and safe way. It also offers Mazor X, a renaissance system and its accessories are used in the spine of the operation, including fusion, spinal deformation correction, biopsy collection, tumor excision, cement and enlargement. The company was previously known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and based in Caesarea, Israel.
Receive news and reviews for Arch Therapeutics Daily – Enter your email address below to get a brief summary of the latest news and analysts reviews by Arch Therapeutics and affiliated companies with FREE Daily Mail MarketBeat.com.